Rosuvastatin: Nursing Drug Guide, Myopathy Risk & NCLEX Review
Rosuvastatin lowers LDL and reduces risk of heart attack and stroke, but nursing safety centers on myopathy and rhabdomyolysis — with distinctive risk in Asian patients, at 40 mg, and with gemfibrozil or cyclosporine. Verify dose caps in renal impairment, check interactions before each dose, and escalate new muscle symptoms or dark urine before kidney injury develops.
Rosuvastatin may cause myopathy and rhabdomyolysis, with higher risk at 40 mg, in Asian patients, with renal impairment, and with gemfibrozil or cyclosporine. Hold and escalate for new muscle pain, muscle weakness, or dark urine; urgent review helps prevent progression to acute kidney injury. Confirm interaction risk before every dose and document symptom onset timing.
📋 Contents
⚡ Quick facts
💡 Key takeaway
Screen muscle symptoms every pass and confirm population-specific dose limits: Asian patients start at 5 mg, and severe renal impairment (not on hemodialysis) should not exceed 10 mg daily. Flag gemfibrozil or cyclosporine combinations, ask about new aches or weakness, and act quickly before CK and creatinine rise together.
Most common brand names
Rosuvastatin is the generic name used in medication orders.
Common brand: Crestor. Confirm formulation and strength to avoid dose-selection errors between 5 mg, 10 mg, 20 mg, and 40 mg tablets.
Why we give it — Indications
Rosuvastatin reduces LDL cholesterol and cardiovascular risk in patients with persistent high blood cholesterol and clinical atherosclerotic disease.
| Use | Nursing relevance |
|---|---|
| Primary hyperlipidemia | Used with diet and risk-factor control to lower LDL and non-HDL cholesterol |
| ASCVD risk reduction | Reduces recurrent event risk in people with established atherosclerosis |
| Diabetes risk profile | Often prescribed in adults with type 2 diabetes and additional cardiovascular risk factors |
On a small screen, swipe or scroll sideways to see the full table.
How it works
Rosuvastatin competitively inhibits HMG-CoA reductase, decreasing hepatic cholesterol synthesis and increasing LDL receptor expression. Clinical effect is tracked by periodic lipid panel trends, while safety monitoring focuses on muscle symptoms and hepatic signal changes.
Dosing overview
Take orally once daily with or without food, at any time of day. Per DailyMed, recommended adult dosage range is 5 to 40 mg once daily. Assess LDL-C when clinically appropriate, as early as 4 weeks after initiation. Asian patients: initiate at 5 mg once daily. Severe renal impairment (not on hemodialysis): initiate at 5 mg once daily; do not exceed 10 mg once daily.
Before you give it — Safety check
Pretreatment checks
- Review baseline cardiovascular indication and current lipid goals
- Check baseline liver function tests and symptom history for prior statin intolerance
- Check medication list for interacting drugs including cyclosporine, gemfibrozil, niacin, colchicine, warfarin, and fibrates
- Screen for untreated contributors to statin myopathy risk such as hypothyroidism
Contraindications (DailyMed)
- Acute liver failure or decompensated cirrhosis
- Hypersensitivity to rosuvastatin or product excipient
Important interactions
| Drug / factor | Risk | Nursing action |
|---|---|---|
| Cyclosporine | Marked rosuvastatin exposure increase; concomitant use not recommended | Hold and consult pharmacy/prescriber; do not administer without revised plan |
| Gemfibrozil | Significant exposure increase; concomitant use not recommended | If unavoidable, labeling limits rosuvastatin to 5 mg start and max 10 mg daily with close monitoring |
| Warfarin | Rosuvastatin may increase INR | Obtain INR before starting and after dose changes; monitor while stable then per protocol |
| Niacin (≥1 g/day) | Additive myopathy risk | Escalate promptly for new proximal weakness or severe myalgia |
| Colchicine | Combined myotoxicity concern, especially renal impairment | Increase monitoring frequency and reassess need for both agents when symptoms appear |
On a small screen, swipe or scroll sideways to see the full table.
Administration
Route: Oral tablet once daily, with or without food, at a consistent administration time.
- Verify current dose strength before administration; 40 mg carries higher myopathy risk than lower doses per labeling
- Evaluate home medication reconciliation each admission to avoid duplicate statin therapy
- Reinforce adherence to antihypertensive, antiplatelet, and glucose plans when co-prescribed (for example aspirin and metformin)
- Maintain continuity with endocrine medications such as levothyroxine to prevent untreated hypothyroid-related muscle complaints
Discontinue rosuvastatin when pregnancy is recognized unless ongoing therapeutic needs are discussed with the prescriber. Breastfeeding is not recommended during rosuvastatin use.
Expected therapeutic response
- LDL reduction and improved non-HDL profile at follow-up lipid testing
- Long-term reduction in recurrent cardiovascular events in indicated populations
- Stable liver and kidney trend data without progressive toxicity signs
- No new muscle complaints requiring interruption
Red flags — Stop and act
Pause dose and escalate promptly when symptoms suggest severe statin toxicity or major hepatic injury.
Adverse effects
| Adverse effect | Clinical context | Nursing response |
|---|---|---|
| Myalgia / mild myopathy | Most frequent muscle-related complaint | Assess severity and pattern; review interactions and thyroid status; escalate if worsening |
| Rhabdomyolysis | Rare but high severity; may include renal injury | Hold dose, urgent prescriber/pharmacy notification, trend CK and renal markers |
| Transaminase elevation | May occur early or after dose changes | Trend labs and symptoms; report sustained elevations with symptoms |
| GI symptoms | Dyspepsia or nausea can occur | Support symptom control while ruling out liver injury when persistent |
| Hyperglycemia trend | Statin class effect; may exceed diabetes diagnostic threshold | Coordinate periodic glucose/HbA1c review with chronic disease plan |
| Proteinuria / hematuria | More frequent at 40 mg; often transient | Consider dose review for unexplained persistent findings on routine urinalysis |
On a small screen, swipe or scroll sideways to see the full table.
Overdose, toxicity, and antidote
DailyMed reports no specific antidote for rosuvastatin overdose. Hemodialysis does not significantly enhance clearance. Treatment is supportive and based on clinical condition.
Labeling guidance
- No specific antidote for rosuvastatin overdose
- Use symptom-directed supportive care and monitor for muscle and hepatic injury patterns
- Escalate through local toxicology services per facility protocol and local emergency guidance
Look-alike / sound-alike and error prevention
- Rosuvastatin vs atorvastatin — potency and interaction pathways differ; verify intended agent
- Rosuvastatin vs pravastatin — different potency and interaction profiles; do not substitute without prescriber order
- Dose-strength mix-ups — 5 mg and 40 mg tablet confusion can produce avoidable toxicity
- Home medication duplication — avoid parallel statin orders after admission reconciliation
Practical bedside notes
| Topic | Bedside guidance |
|---|---|
| Muscle symptom interview | Ask location, onset, severity, and progression each shift in symptomatic or high-risk patients |
| Interaction check | Confirm med changes after transfers and consult pharmacy before dose escalation |
| Renal warning signs | Track urine color and output when muscle injury is suspected |
| Hepatic warning signs | Pair symptom interview with trend review of transaminases and bilirubin |
| Missed-dose counseling | Reinforce: do not take an extra dose; resume usual schedule |
On a small screen, swipe or scroll sideways to see the full table.
High-risk populations
| Population | Considerations |
|---|---|
| Older adults and frail patients | Higher symptom-report barriers; schedule proactive checks rather than waiting for complaints |
| Asian patients | Higher myopathy risk; initiate at 5 mg and titrate cautiously |
| Severe renal impairment | Start 5 mg; do not exceed 10 mg daily if not on hemodialysis |
| Gemfibrozil or cyclosporine exposure | Concomitant use not recommended; high muscle injury risk |
| Chronic kidney disease | Monitor for pigment nephropathy when muscle injury develops; severe impairment dose cap 10 mg if not on hemodialysis |
| Endocrine comorbidity | Uncontrolled hypothyroidism increases myopathy susceptibility |
| Pregnancy or planned conception | Discontinue when pregnancy recognized unless specialist-directed exception |
| Lactation | Breastfeeding is not recommended during therapy |
On a small screen, swipe or scroll sideways to see the full table.
Monitoring and documentation
Monitor
- Serial symptom screen for myalgia, weakness, cramps, and functional decline
- Lipid response and adherence trends; coordinate HbA1c plans where diabetes risk is high
- Hepatic trends including ALT and AST when clinically indicated
- Renal and metabolic trends when rhabdomyolysis is suspected
| Priority lab | Use in rosuvastatin safety workflow |
|---|---|
| ALT | Investigate hepatocellular injury when symptoms or transaminase rise appears |
| AST | Trend with ALT for hepatic signal consistency |
| Basic metabolic panel | Tracks creatinine/electrolyte impact when rhabdomyolysis concern exists |
| HbA1c | Supports long-term cardiometabolic risk review |
| INR | Track when warfarin is co-prescribed because rosuvastatin may increase INR |
On a small screen, swipe or scroll sideways to see the full table.
Document
- Exact symptom wording and onset relative to dose timing
- Interaction review performed before administration
- Hold actions and provider-pharmacist notifications
- Follow-up plans and patient teach-back for muscle symptom reporting
Patient teaching
- Report any new diffuse muscle pain, weakness, or cola-colored urine right away
- Do not take an extra dose after a missed tablet; resume the usual schedule
- Tell clinicians about all new prescriptions and supplements before restarting or increasing statin dose
- Discontinue and contact the care team immediately if pregnancy is recognized
- Do not breastfeed while taking rosuvastatin
The Hold Rule
Do not give and contact the prescriber/pharmacist when:
- New unexplained generalized muscle pain, weakness, or dark urine is present
- Acute liver failure, decompensated cirrhosis, or documented hypersensitivity is present
- Gemfibrozil or cyclosporine is co-prescribed without a documented safety plan
- Ordered dose exceeds renal or Asian population limits without prescriber clarification
- Major interacting medication is started without updated dose/monitoring plan
- Pregnancy recognized and no specialist continuation plan is documented
- Rapidly rising CK or creatinine suggests evolving rhabdomyolysis pathway
Hold parameters can vary by institution. Follow prescriber orders, pharmacy guidance, and local policy.
Clinical practice integration and workflow
Rosuvastatin errors often involve gemfibrozil or cyclosporine combinations, dose overshoot in Asian or renal-impaired patients, or delayed recognition of early muscle toxicity. Build a workflow centered on population-specific dosing and rapid escalation.
1. Check-before-you-give protocol
- Verify right drug, strength, and schedule against current indication
- Ask focused muscle-symptom question before dose
- Screen medication updates for interaction risk
- Review latest liver and kidney trend data if symptoms are present
2. High-alert and safety badge
Rhabdomyolysis risk — population dosing and interaction vigilanceRosuvastatin is potent at low milligram strengths. Asian patients, renal dose caps, and gemfibrozil combinations raise myopathy risk — treat new proximal symptoms as a safety event until evaluated.
3. Clinical workflow: hold and question rules
- If muscle symptoms appear after a medication change, hold and trigger interaction review before next dose
- If CK and creatinine rise together, escalate for rhabdomyolysis pathway and supportive management
- If transaminases trend up with systemic symptoms, clarify continuation plan same day
4. Critical teach-back questions
- “What symptoms mean you should call us before the next dose?” (Patient should include severe muscle pain, weakness, and dark urine.)
- “What do you do if you miss a dose?” (Patient should say do not take an extra dose and resume the usual schedule.)
5. Care coordination
Pharmacist: Interaction stratification, dose optimization, and escalation thresholds for muscle toxicity
Prescriber / cardiology / primary team: Ongoing lipid strategy, adverse event decision-making, and post-hold rechallenge planning
🧠 Quick mental checklist
- Any new proximal pain, weakness, or reduced activity tolerance today?
- Any change in urine color, urine output, or creatinine trend?
- Any newly added interacting medications since the last administration?
- Are hold criteria clearly documented and understood by patient and team?
- Has missed-dose teaching been reinforced in plain language?
Rosuvastatin NCLEX practice questions
Rehearse NCLEX-style clinical judgment practice for rosuvastatin using a tabbed case panel (MAR, labs, history, nursing notes), then priority action, SATA cue recognition, trend interpretation, matrix urgency judgment, missed-dose decision, and overdose cloze documentation focused on gemfibrozil interaction and Asian renal dosing safety.
Select a tab to view MAR, labs, history, and nursing note details for this case.
- Rosuvastatin 20 mg PO nightly at 2100
- Gemfibrozil 600 mg PO twice daily (started 9 days ago)
- Warfarin 4 mg PO daily
- Metformin 500 mg PO twice daily
- Levothyroxine 50 mcg PO daily
- Day 0: CK 118 U/L, creatinine 1.4 mg/dL, LDL 148 mg/dL, INR 2.4
- Day 5: CK 420 U/L, creatinine 1.5 mg/dL
- Day 9: CK 1260 U/L, creatinine 1.9 mg/dL, AST 68 U/L, ALT 62 U/L
- Urinalysis today: dipstick positive for blood with microscopic hematuria
- 71-year-old Asian American with hyperlipidemia and stage 4 CKD (eGFR 24 mL/min/1.73 m²)
- On rosuvastatin 20 mg for 6 months without prior myopathy
- Gemfibrozil added by outpatient clinic for elevated triglycerides
- Not on hemodialysis
- Reports bilateral thigh and hip pain worsening over 3 days
- Difficulty standing from chair; urine darker than usual
- No chest pain or shortness of breath; tolerating oral intake
- 2100 rosuvastatin dose due in 30 minutes
Answer key & rationale
Frequently asked questions
What makes rosuvastatin muscle toxicity high priority in nursing care?
Myopathy and rhabdomyolysis can progress quickly when interaction risk or symptom changes are missed. Nurses should escalate new muscle pain, weakness, and dark urine immediately and hold doses pending review.
Is active liver disease an absolute contraindication to rosuvastatin?
The current DailyMed contraindications list acute liver failure or decompensated cirrhosis and hypersensitivity. Active liver disease is not listed as a standalone contraindication in that section.
What should patients do if pregnancy is recognized while taking rosuvastatin?
Discontinue rosuvastatin when pregnancy is recognized unless specialist-directed continuation is considered essential for very high-risk disease.
How should a missed rosuvastatin dose be handled?
Do not take an extra dose. Resume the usual schedule at the next planned time.
Is there an antidote for rosuvastatin overdose?
No specific antidote is available. Management is supportive and symptom-directed with close monitoring.
Why are gemfibrozil and Asian dosing high priority with rosuvastatin?
DailyMed states concomitant cyclosporine or gemfibrozil is not recommended. Also verify Asian 5 mg start, severe renal 10 mg cap, warfarin INR plans, and colchicine or niacin combinations.
References
- U.S. National Library of Medicine. Rosuvastatin tablet — Full prescribing information. DailyMed.https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3ffe0294-3997-2755-e054-00144ff8d46c
- U.S. Food and Drug Administration. MedWatch: FDA Safety Information and Adverse Event Reporting Program.https://www.fda.gov/safety/medwatch-fda-safety-information-and-adverse-event-reporting-program
- American Heart Association. About cholesterol.https://www.heart.org/en/health-topics/cholesterol/about-cholesterol
Review and transparency
This medication guide is written and reviewed using NurseOnShift editorial and clinical review standards.
Educational use only. This content does not replace clinical judgment, prescriber orders, pharmacist guidance, product labeling, or institutional protocols.